Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

NCT01184326 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT01184326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01184326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2011
Completion date
March 31, 2017
Enrollment
23 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer, solid tumor